Dr. Kisa Weeman

Hematology | Oncology
Aultman Hospital
2600 6th St SW, 
Canton, OH 
Aultman Hospital
2600 6th St SW, 
Canton, OH 

Overview

Kisa Weeman is a Hematologist and an Oncologist practicing medicine in Canton, Ohio.

Her clinical expertise encompasses Lung Cancer and Breast Cancer.

She is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 19 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in OH

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Aultman Hospital
2600 6th St SW, Canton, OH 44710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women With Dense Breasts
Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women With Dense Breasts
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2026
Intervention Type: Other, Diagnostic test
Study Phase: Not Applicable
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
View 9 Less Clinical Trials

3 Total Publications

Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative.
Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative.
Journal: JCO precision oncology
Published: December 18, 2020
Similar Doctors
Expertise in
25
conditions
Dr. Jason Valent
Hematology | Oncology
Expertise in
25
conditions
Dr. Jason Valent
Hematology | Oncology
Referral may be required

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (50.1 miles away)
216-444-6833
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Valent is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Valent is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

Expertise in
23
conditions
Dr. Brad Pohlman
Hematology | Oncology
Expertise in
23
conditions
Dr. Brad Pohlman
Hematology | Oncology
Referral may be required

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (50.1 miles away)
216-445-6070
Languages Spoken:
English
See accepted insurances

Brad Pohlman is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Pohlman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
33
conditions
Dr. Robert Dean
Hematology | Oncology
Expertise in
33
conditions
Dr. Robert Dean
Hematology | Oncology
Referral may be required

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (50.1 miles away)
216-444-6833
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Dean is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Dean is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Kisa Weeman

How do I make an appointment with Dr. Kisa Weeman?

You can book an appointment with Dr. Kisa Weeman by calling their office at 330-363-4363. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kisa Weeman a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kisa Weeman is classified as an Experienced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kisa Weeman specialize in?

While Dr. Kisa Weeman is a Hematology, they have specific expertise in Lung Cancer, Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kisa Weeman participate in research or clinical trials?

Yes. Dr. Kisa Weeman has published 3 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Kisa Weeman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weeman's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile